神经损伤与功能重建2025，Vol.20Issue(10)：580-583,4.DOI:10.16780/j.cnki.sjssgncj.20250071
尿激酶原、瑞替普酶和替奈普酶治疗急性缺血性卒中的研究进展
Research Advances in Prourokinase,Reteplase,and Tenecteplase for Acute Ischemic Stroke Treatment
杨富文 1马变君 1范茗华 2王燕宏1
作者信息
- 1. 山西医科大学第三临床医学院 太原 030000||山西白求恩医院神经内科 太原 030000
- 2. 山西白求恩医院神经内科 太原 030000
- 折叠
摘要
Abstract
Stroke ranks among the leading causes of global disease burden,injury,and risk factors,with acute ischemic stroke(AIS)accounting for approximately 75%of cases.Intravenous thrombolysis stands as one of the most effective treatments for AIS,enabling rapid recanalization of occluded vessels and restoration of blood flow to minimize disability or mortality risks in patients.In recent years,novel intravenous thrombolytic agents with favorable safety profiles and distinct therapeutic benefits have gained significant attention.This review sys-tematically summarizes evidence from multicenter studies and explores potential mechanisms underlying three such drugs—prourokinase,reteplase,and tenecteplase—aiming to provide theoretical support for advancing clin-ical research and deepening insights into their mechanisms of action.关键词
急性缺血性卒中/静脉溶栓/尿激酶原/瑞替普酶/替奈普酶Key words
acute ischemic stroke/intravenous thrombolysis/prourokinase/reteplase/tenecteplase分类
医药卫生引用本文复制引用
杨富文,马变君,范茗华,王燕宏..尿激酶原、瑞替普酶和替奈普酶治疗急性缺血性卒中的研究进展[J].神经损伤与功能重建,2025,20(10):580-583,4.
